Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more
Market Cap & Net Worth: Laboratorios Richmond SACIF (RICH)
Laboratorios Richmond SACIF (BA:RICH) has a market capitalization of $117.46 Million (AR$122.18 Billion) as of March 18, 2026. Listed on the BA stock exchange, this Argentina-based company holds position #24460 globally and #44 in its home market, demonstrating a 14.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Laboratorios Richmond SACIF's stock price AR$1835.00 by its total outstanding shares 66584323 (66.58 Million).
Laboratorios Richmond SACIF Market Cap History: 2017 to 2026
Laboratorios Richmond SACIF's market capitalization history from 2017 to 2026. Data shows growth from $2.00 Million to $117.46 Million (64.73% CAGR).
Laboratorios Richmond SACIF Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Laboratorios Richmond SACIF's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Laboratorios Richmond SACIF's market cap is 0.00 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.00x
Laboratorios Richmond SACIF's market cap is 0.00 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.00 Million | $982.22 Million | $40.76 Million | 0.00x | 0.05x |
| 2018 | $2.32 Million | $1.82 Billion | -$215.60 Million | 0.00x | N/A |
| 2019 | $7.41 Million | $3.90 Billion | $116.44 Million | 0.00x | 0.06x |
| 2020 | $7.38 Million | $6.18 Billion | $486.24 Million | 0.00x | 0.02x |
| 2021 | $14.21 Million | $16.62 Billion | $591.46 Million | 0.00x | 0.02x |
| 2022 | $24.90 Million | $18.47 Billion | $163.43 Million | 0.00x | 0.15x |
| 2023 | $44.81 Million | $84.99 Billion | -$23.63 Billion | 0.00x | N/A |
| 2024 | $114.90 Million | $91.79 Billion | $23.85 Billion | 0.00x | 0.00x |
Competitor Companies of RICH by Market Capitalization
Companies near Laboratorios Richmond SACIF in the global market cap rankings as of March 18, 2026.
Key companies related to Laboratorios Richmond SACIF by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Laboratorios Richmond SACIF Historical Marketcap From 2017 to 2026
Between 2017 and today, Laboratorios Richmond SACIF's market cap moved from $2.00 Million to $ 117.46 Million, with a yearly change of 64.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AR$117.46 Million | -5.90% |
| 2025 | AR$124.82 Million | +8.64% |
| 2024 | AR$114.90 Million | +156.43% |
| 2023 | AR$44.81 Million | +79.95% |
| 2022 | AR$24.90 Million | +75.23% |
| 2021 | AR$14.21 Million | +92.63% |
| 2020 | AR$7.38 Million | -0.43% |
| 2019 | AR$7.41 Million | +219.56% |
| 2018 | AR$2.32 Million | +15.73% |
| 2017 | AR$2.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Laboratorios Richmond SACIF was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $117.46 Million USD |
| MoneyControl | $117.46 Million USD |
| MarketWatch | $117.46 Million USD |
| marketcap.company | $117.46 Million USD |
| Reuters | $117.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.